VIRIDIAN THERAPEUTICS, INC.
Last · NasdaqCM$18.38+0.16 (+0.88%)close · yahoo · 10h ago
Market cap$2.08B113.3M sh
P/E · TTM-5.4fwd -6.7 · eps -3.39 · loss
Beta1.10vs S&P 500
Div yield0.00%annual · TTM
52w range
$13.18$34.29
Volume3.7Msession
| Revenue | $70.8M |
|---|---|
| Operating income | $-363.4M |
| Net income | $-342.6M |
| Free cash flow | $-276.9M |
| Operating margin | -512.9% |
| Net margin | -483.6% |
| Return on equity | -47.4% |
| Period | 2025 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-02-26
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Accumulated Deficit High
- Rd Intensity High
Red flags
- Sbc Revenue High — SBC/Revenue 62.5%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -483.6%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -390.1%
- Cash Runway Low — Cash runway ~0.8 years
- Accumulated Deficit High — Accumulated deficit / equity 185%
- Rd Intensity High — R&D/Revenue 478.4%
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$1.02
Est. revenue
9.9M
Earnings transcripts
Documents
FormReporting forFiledFlags